Amelioration of inflammatory bowel disease by Bifidobacterium animalis subsp. lactis XLTG11 in combination with mesalazine

The treatment of inflammatory bowel disease (IBD) remains challenging and significantly impacts both patients and their families. This study evaluated the role of Bifidobacterium animalis subsp. lacti XLTG11 (XLTG11) in combination with mesalazine (5-ASA) in the improvement of IBD. The results demon...

Full description

Bibliographic Details
Published in:Frontiers in Microbiology
Main Authors: Weiwei Ma, Yanan Wu, Xinyue Lin, Liping Yang, Lili Huang
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Subjects:
Bifidobacterium animalis subsp. lacti
mesalazine
IBD
intestinal microorganisms
SCAFs
Online Access:https://www.frontiersin.org/articles/10.3389/fmicb.2024.1472776/full

Internet

https://www.frontiersin.org/articles/10.3389/fmicb.2024.1472776/full

Similar Items